Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
Date:7/30/2013

tests.

Financial ResultsRevenues:  Lexicon's revenues for the three months ended June 30, 2013 were $0.2 million, consistent with the corresponding period in 2012.  For the six months ended June 30, 2013, revenues increased to $0.6 million from $0.5 million for the corresponding period in 2012.

Research and Development Expenses:  Research and development expenses for the three months ended June 30, 2013 increased 22 percent to $23.7 million from $19.4 million for the corresponding period in 2012.  The increase was primarily attributable to increases in external clinical and preclinical research and development and personnel costs, partially offset by decreases in facility costs.  For the six months ended June 30, 2013, research and development expenses increased four percent to $44.0 million from $42.4 million for the corresponding period in 2012.

Increase in Fair Value of Symphony Icon Purchase Liability:  In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated base and contingent payments.  Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.  The increase in fair value of the Symphony Icon purchase liability was $0.5 million and $2.2 million for the three months ended June 30, 2013 and 2012, respectively, and was $1.7 million and $4.2 million for the six months ended June 30, 2013 and 2012, respectively. 

General and Administrative Expenses:  General and administrative expenses for the three months ended June 30, 2013 increased 12 percent to $4.7 million from $4.2 million for the corresponding period in 2012.  The increase was primarily attributable to increases in personnel costs and legal and patent fees.  For the six months ended June 30, 201
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lexicon to Report Second Quarter Financial Results on July 30, 2013
2. Lexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In Clinical Trial of LX4211
3. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
4. Lexicon To Present At The Goldman Sachs Global Healthcare Conference
5. Lexicon To Present At The Jefferies Global Healthcare Conference
6. Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
7. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
8. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
9. Lexicon to Report First Quarter Financial Results on May 10, 2013
10. Lexicon To Present At The Needham Healthcare Conference
11. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 ... Market Research Report on Global and China Lysine ... is a professional and the deep research report ... introduces Lysine basic information including definition, classification specifications, ... as US, Europe , ...
(Date:4/17/2015)... WOONSOCKET, R.I , April 17, 2015 ... holding a conference call on Friday, May 1, 2015, ... discuss its first quarter financial results. An ... simultaneously through the Investor Relations portion of the CVS ... webcast, visit http://investors.cvshealth.com . This webcast will be ...
(Date:4/17/2015)... April 17, 2015  Trovagene, Inc., (NASDAQ:  TROV) ... that clinical data presented at the 2015 European ... Precision Cancer Monitoring ℠ (PCM) platform outperformed ... EGFR T790M mutations in metastatic lung ... EGFR T790M Mutation in Urinary Circulating Tumor DNA ...
Breaking Medicine Technology:Lysine Market International (US, Europe, Japan) Research Analysis 2Lysine Market International (US, Europe, Japan) Research Analysis 3Lysine Market International (US, Europe, Japan) Research Analysis 4Lysine Market International (US, Europe, Japan) Research Analysis 5Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4
(Date:4/18/2015)... For some people, tattoos are works of art that ... their lives, as they have spent a great deal of ... amount of thought on their designs. For others, however, tattoos ... simply want them removed for personal or professional reasons. In ... 2012-13 there was a 43 percent increase in the number ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 Carinsurancehints.com has released ... insurance plans that offer financial protection against fire damage. ... will pay benefits in case their vehicle is set intentionally ... vandalism caused by rioting or by other things. , ... quotes on a single website http://www.carinsurancehints.com/ , in ...
(Date:4/18/2015)... Lowcostcarinsuranceprice.com has released a new blog ... auto insurance prices . , Drivers who ... theft may have to pay more for auto insurance ... policies can also offer protection against vehicle theft. ... online on a single website: http://lowcostcarinsuranceprice.com/ . ...
(Date:4/18/2015)... More than 2000 styles of newly ... the #1 online store carrying celebrity inspired special occasion ... got their perfect dresses for their prom. For those ... dresses at TheCelebrityDresses.com would be an ideal choice. ... prom dresses inspired by the most loved styles seen ...
(Date:4/18/2015)... Montreal, Canada (PRWEB) April 18, 2015 ... of emotions on food choices when he uttered, “Tell ... what you are.” Using food to cope with stress ... research by Queendom.com indicates otherwise. Data collected ... both genders fall victim to emotional eating, but for ...
Breaking Medicine News(10 mins):Health News:Dennis Dass, M.D. is Shattering the Past While Revealing the Future 2Health News:Online Auto Insurance Quotes For Plans That Cover Fire Damages! 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6
... , OAKLAND, Calif., Aug. 5 Anyone ... record in a standardized format understood at hospitals, clinics and ... specializing in chronic illness support, geriatric care management and private ... Your Own Health to re-brand and sell the popular ...
... , , PHOENIX, Aug. 5 ... hand must not become a vehicle for taking lives through abortion ... report at the organization,s 127th annual convention here today. Referring to ... declared that "Health care reform must be abortion-free." , , ...
... direction for diabetes treatment , WEDNESDAY, Aug. 5 (HealthDay News) ... role in the control of blood sugar production in the ... first time that CCK from the gut activates receptors to ... axis," Tony Lam of the University of Toronto said in ...
... , , , ... a privately-held specialty pharmaceutical company, today announced that it has ... IMS data indicates the combined U.S. market for these two ... and shipping both products immediately. , , ...
... an animal model that provides strong evidence why imatinib, marketed ... but does not keep the disease from returning if treatment ... drug,s radar and enable the disease to recur in most ... issue of Cancer Cell . The researchers ...
... An internationally recognized Virginia Commonwealth University physician has ... Award for his pioneering contributions that have advanced the ... past recipients who have made a remarkable impact on ... Foundation for Infectious Diseases awarded the honor to Richard ...
Cached Medicine News:Health News:Portable Health Care Records Now Available for Consumers 2Health News:'Health Care Reform Must be Abortion-Free,' says Supreme Knight 2Health News:Sagent Pharmaceuticals Announces Launch of First Two Oncolytic Products: Fludarabine Phosphate for Injection, USP and Epirubicin Hydrochloride Injection 2Health News:Finding key to cancer drug Gleevec's limitations 2Health News:National Foundation for Infectious Diseases honors VCU physician with Maxwell Finland Award for 2010 2Health News:National Foundation for Infectious Diseases honors VCU physician with Maxwell Finland Award for 2010 3
... 5 system is an intuitive, all-in-one ... to minimize the scarring and risk ... procedures. Incorporating an enhanced, ergonomic handle ... operative obstructions, this new device is ...
... The Arrow LionHeart Left Ventricular Assist System ... designed to be used as a destination ... (Class IV) congestive heart failure, for which ... Arrow LionHeart LVAS is not intended as ...
... The TandemHeart PTVA ( Percutaneous ... proprietary solution for the hemodynamic needs of ... and Cardiac Surgeons. These specialists have ... some coronary artery perfusion, but the IABP ...
The MicroMed DeBakey VAD is a miniaturized heart pump designed to provide increased blood flow (up to 10L/min) from the left ventricle of the heart throughout the body for patients in end stage heart...
Medicine Products: